Angle PLC
LSE:AGL

Watchlist Manager
Angle PLC Logo
Angle PLC
LSE:AGL
Watchlist
Price: 9.35 GBX Market Closed
Market Cap: 30.2m GBX
Have any thoughts about
Angle PLC?
Write Note

Angle PLC
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Angle PLC
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Angle PLC
LSE:AGL
Cost of Revenue
-ÂŁ626k
CAGR 3-Years
-51%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Cost of Revenue
-$1.7B
CAGR 3-Years
-4%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Cost of Revenue
-$400.1m
CAGR 3-Years
-2%
CAGR 5-Years
-3%
CAGR 10-Years
-31%
EKF Diagnostics Holdings PLC
LSE:EKF
Cost of Revenue
-ÂŁ26.5m
CAGR 3-Years
10%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Creo Medical Group PLC
LSE:CREO
Cost of Revenue
-ÂŁ15.3m
CAGR 3-Years
-8%
CAGR 5-Years
-449%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Cost of Revenue
-$1.8m
CAGR 3-Years
N/A
CAGR 5-Years
-48%
CAGR 10-Years
N/A
No Stocks Found

Angle PLC
Glance View

Market Cap
30.2m GBX
Industry
Health Care

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

AGL Intrinsic Value
21.81 GBX
Undervaluation 57%
Intrinsic Value
Price

See Also

What is Angle PLC's Cost of Revenue?
Cost of Revenue
-626k GBP

Based on the financial report for Jun 30, 2024, Angle PLC's Cost of Revenue amounts to -626k GBP.

What is Angle PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-51%

Over the last year, the Cost of Revenue growth was 13%. The average annual Cost of Revenue growth rates for Angle PLC have been -51% over the past three years .

Back to Top